This educational activity is designed to incorporate evidence-based pathophysiology, diagnosis, and/or treatment of urologic disorders into clinical practice. Speakers will utilize their personal, institutional and evidence-based experience to address patient health care conditions requiring clinical and surgical treatment. Speakers will also utilize departmental quality improvement data, M&M data, and patient safety data to improve outcomes of urologic disease and other aspects of urologic patients’ general health. Evidence-based data regarding the changing aspects/newer approaches to surgical disease will be analyzed, and critical issues related to urology within the broader scope of American health care will be discussed. There are varying degrees to individuals’ knowledge regarding clinical and urologic treatments. While individuals may be aware of varied treatment within the urologists’ armamentarium it is beneficial to address the topics from an evidence-based approach.
- Urology Faculty
- Allied Healthcare Providers
- Community Physicians
- The participant will understand the clinical diagnosis of Peyronie’s disease.
- The participant will understand the American Urological Association’s guideline for the treatment of Peyronie’s disease.
- The participant will learn about potential treatments which are being developed for the treatment of Peyronie’s disease.
Role in Meeting:
|Nathan Grunewald, MD||Speaker|
|Ken Jacobsohn, MD||Planning Committee|
|William See, MD||Planning Committee|
All persons in control of content have no relevant financial relationships to disclose with the exception of the following person:
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.